New Research Advance: Lithium/GSK3 for Fragile X

New Research Advance: Lithium/GSK3 for Fragile X

Two new papers from FRAXA-funded researcher Dr. Richard Jope demonstrate the potential of GSK3 inhibitors, including the available drug, lithium, to reverse learning deficits in fragile X. Dr. Jope has previously shown that lithium and other more specific inhibitors of the enzyme Glycogen Synthase Kinase 3 (GSK3) can rescue key symptoms in Fragile X mice. These new publications take that study a step further by showing that lithium (at usual therapeutic doses) and investigational GSK3 inhibitors could reverse a number of cognitive deficits in the mice. The Jope group showed that Fragile X mice are abnormal in novel object recognition, spatial memory, and temporal order memory, and that these GSK3-inhibiting compounds could all reverse these defects, along with associated electrophysiological abnormalities. Furthermore, in the short term, these abnormalities were relatively insensitive to treatment with an mGluR5 antagonist (although other studies suggest that prolonged treatment with mGluR5 antagonists can correct these

Read more

Glycogen Synthase Kinase-3 and Fragile X

Glycogen Synthase Kinase-3 and Fragile X

With $208,000 in funds from FRAXA Research Foundation, Dr. Richard Jope and his team at the University of Miami tested whether newly developed, highly specific inhibitors of GSK3 can reduce behavioral abnormalities in fragile X mice.

Read more